Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | RAF1 | P04049 | 17/20 | 0.49 |
| ▸ | BRAF | P15056 | 17/20 | 0.49 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.46 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12029338 | 0.93 | GAA (0.43) | KDM4EGAARAF1BRAFSCN9A | |
| SCHEMBL12029339 | 0.87 | CNR2 (0.53) | KDM4EGAARAF1BRAFTRPV4 | |
| SCHEMBL12029343 | 0.86 | KDM4E (0.49) | KDM4EGAARAF1BRAF | |
| SCHEMBL12029337 | 0.84 | RAF1 (0.48) | KDM4EGAARAF1BRAF | |
| SCHEMBL12029170 | 0.82 | BRAF (0.50) | GAARAF1BRAF | |
| SCHEMBL12029384 | 0.81 | MAP3K7 (0.46) | KDM4EGAABRAFTRPV4 | |
| SCHEMBL12029173 | 0.81 | BRAF (0.53) | GAARAF1BRAF | |
| SCHEMBL12029205 | 0.81 | CSF1R (0.50) | GAARAF1BRAF | |
| SCHEMBL12029331 | 0.81 | CNR2 (0.46) | TRPV4 | |
| SCHEMBL12029175 | 0.81 | KIT (0.51) | GAARAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9326986-B2 | Quinazolinone, quinolone and related analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2016-05-03 | — | — | US | disclosed |
| US-9326986-B2 | Quinazolinone, quinolone and related analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2016-05-03 | — | — | US | disclosed |
| EP-2344475-B1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2014-07-30 | — | — | EP | disclosed |
| US-20110306612-A1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110306612-A1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| WO-2010037129-A1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS INC. (US) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306612-A1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT3, SIRT1, SIRT2 | KDM4E 1577/4885GAA 809/4885RAF1 1643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.